Nuclear p62/SQSTM1 facilitates ubiquitin-independent proteasomal degradation of BMAL1
PLOS Genetics · 2025
DOI: 10.1371/journal.pgen.1011794 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Genetics, 2025. Verfasst von Chenliang Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in On…. Hauptthemen laut MEDLINE: ARNTL Transcription Factors, Sequestosome-1 Protein, Proteasome Endopeptidase Complex. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Province Science and Technology Support Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Brain and muscle arnt-like protein 1(BMAL1) is a critical regulator of circadian rhythm. Although transcriptional regulation of BMAL1 has been extensively studied, the mechanisms governing the stability of BMAL1 at the protein level remain unclear. p62/SQSTM1 is a crucial factor in proteostasis regulation and is involved in both autophagy and the ubiquitin-proteasome system. We demonstrated that p62 promotes proteasomal degradation of BMAL1 within the nucleus, independent of ubiquitination. Additional molecular analyses indicated that p62 functions as a receptor for the 20S proteasome, facilitating the recruitment of BMAL1 to the 20S proteasome for degradation. This mechanism is independent of recently identified p62-driven nuclear biomolecular condensates. We also revealed that remodeling the nuclear accumulation of p62 may represent a potential strategy for targeting BMAL1 to suppress tumor cell growth. In conclusion, our findings revealed a novel mechanism by which nuclear p62 regulates BMAL1 proteostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Prov…
- Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
- Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
- West China School of Medicine, Sichuan University, Chengdu, Sichuan Province, China.
- Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
ORCID-Profile: Chenliang Zhang
Förderung
- Sichuan Province Science and Technology Support Program
- National Natural Science Foundation of China
Zitieren
APA
Zhang, C., Wu, Q., Zhang, H., Liu, R., & Li, L. (2025). Nuclear p62/SQSTM1 facilitates ubiquitin-independent proteasomal degradation of BMAL1. PLOS Genetics. https://doi.org/10.1371/journal.pgen.1011794
Vancouver
Zhang C, Wu Q, Zhang H, Liu R, Li L. Nuclear p62/SQSTM1 facilitates ubiquitin-independent proteasomal degradation of BMAL1. PLOS Genetics. 2025. doi:10.1371/journal.pgen.1011794
BibTeX
@article{Zhang2025,
author = {Zhang, Chenliang and Wu, Quanyou and Zhang, Huan and Liu, Ruichen and Li, Liping},
title = {Nuclear p62/SQSTM1 facilitates ubiquitin-independent proteasomal degradation of BMAL1},
journal = {PLOS Genetics},
year = {2025},
doi = {10.1371/journal.pgen.1011794}
}
EUVIMED